ALZA GAINS ON CATAPRES TTS "APPROVABLE" ANNOUNCEMENT; INDEX DECLINES
Executive Summary
Robins (up 1-1/2 to 17) and Alza (up 1-3/8 to 18-1/4) were the only point-plus gainers among listed stocks on the Pharmaceutical Component of the "F-D-C" Weekly Index for the week ended Sept. 7. Alza advanced on the announcement that Boehringer Ingelheim's Catapres TSS, a once-weekly forumulation of clonidine using Alza's controlled-release drug delivery technology, had reached the "approvable" stage at FDA. For the week, both Pharmaceutical and Diversified Components slumped 1.3%, pushing the Composite down 1.2%, while the Dow dipped 1.4%. Chart omitted.